Company Description
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders.
Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.
The company’s pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which is in phase 3clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor.
It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth.
The company was founded in 1997 and is headquartered in Salt Lake City, Utah.
| Country | United States |
| Founded | 1997 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 16 |
| CEO | Mahesh Patel |
Contact Details
Address: 675 Arapeen Drive, Suite 202 Salt Lake City, Utah 84108 United States | |
| Phone | 801 994 7383 |
| Website | lipocine.com |
Stock Details
| Ticker Symbol | LPCN |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001535955 |
| CUSIP Number | 53630X104 |
| ISIN Number | US53630X2036 |
| Employer ID | 99-0370688 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Mahesh V. Patel Ph.D. | Co-Founder, Interim Principal Financial Officer, Director, President and Chief Executive Officer |
| Krista Fogarty | Principal Accounting Officer and Corporate Controller |
| Dr. Nachiappan Chidambaram Ph.D. | Senior Vice President of Research and Development |
| Logan Morse | Vice President of Sales, Marketing and Operations |
| Dr. Anthony DelConte M. D., M.D. | Chief Medical Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 10, 2025 | PRE 14A | Other preliminary proxy statements |
| Apr 3, 2025 | 8-K | Current Report |
| Mar 26, 2025 | 8-K | Current Report |
| Mar 13, 2025 | 8-K | Current Report |
| Mar 13, 2025 | 10-K | Annual Report |
| Mar 12, 2025 | 8-K | Current Report |
| Feb 11, 2025 | 8-K | Current Report |
| Feb 6, 2025 | 8-K | Current Report |
| Jan 13, 2025 | 8-K | Current Report |
| Dec 17, 2024 | 8-K | Current Report |